Europe
Most women who survive beyond 10 years die of non-cancer causes
Companies from across the globe provide updates on their business and product pipelines.
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
FerGene launched last month with a $570 million investment from Ferring and Blackstone Life Sciences.
Summit Therapeutics plc reports its financial results and provides an update on its operational progress for the third quarter and nine months ended 31 October 2019.
UK based MR Solutions presented a simultaneous 7T PET/MRI preclinical imaging system optimized for nanoparticle imaging to the first joint annual congress of the French Nanomedicine Society, and the French national Competency Cluster in Nanoscience C’Nano which was held in Dijon in early December.
GPCR biosensor technology, developed via support of CQDM, Merck and Pfizer, recognized as breakthrough approach in GPCR characterization
Recipharm, the contract development and manufacturing organisation has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut® Technology, have announced a partnership to commercialise the cell delivery potential of the polymer-based ‘bionic’ nanoparticles, which can carry a range of payloads directly to live cells.
IBA, the world’s leading provider of solutions for the diagnosis and treatment of cancer, announces that it has sold RadioMed Corporation, IBA’s VISICOIL™ fiducial markers business, to IZI Medical Products LLC, a leading interventional medical device company in a deal that is worth between USD 14 and 16 million to IBA.
PRESS RELEASES